Drug Profile

AXER 204

Alternative Names: AXER-204; human Nogo Receptor decoy; human NoGo Trap

Latest Information Update: 01 Sep 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ReNetX Bio
Class Proteins; Recombinant fusion proteins
Mechanism of Action Myelin-associated glycoprotein inhibitors; Nogo protein inhibitors; Oligodendrocyte myelin glycoprotein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

21 Jun 2022 ReNetX Bio completes a phase I/II RESET trial in Spinal cord injuries in USA (Intrathecal) (NCT03989440)
19 Jun 2019 the US FDA approves IND application for AXER 204 in chronic Spinal cord injury
01 Jun 2019 Phase-I/II clinical trials in Spinal cord injuries in USA (Intrathecal) (NCT03989440)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com